Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REL-1017 Monotherapy in Major Depressive Disorder
NCT05081167Phase 3Completed
- Sponsor
- Relmada Therapeutics, Inc.
- Start
- Jun 2021
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of esmethadone in major depressive disorder (MDD), sponsored by Relmada Therapeutics, Inc.. Started Jun 2021; status: completed.
02
Drugs
esmethadone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05081167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05081167.